Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)

被引：0
|
作者：
Beal, K. [1 ]
Omuro, A. [1 ]
Karimi, S. [1 ]
Correa, D. [1 ]
Chan, T. A. [1 ]
DeAngelis, L. M. [1 ]
Yamada, Y. [1 ]
Abrey, L. E. [1 ]
Gutin, P. H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [41] FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Kerloeguen, Yannick
    Guijarro, Abajo
    Cloughsey, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 105 - 106
  • [42] PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca
    Liu, Diane
    Sanqui, Edmund
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara
    de Groot, John
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [43] A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)
    Gan, Hui K.
    Fichtel, Lisa
    Lassman, Andrew B.
    Merrell, Ryan
    van den Bent, Martin
    Kumthekar, Priya
    Scott, Andrew M.
    Pedersen, Michelle
    Gomez, Erica
    Fischer, JuDee
    Ames, William
    Xiong, Hao
    Dudley, Matt
    Munasinghe, Wijith
    Roberts-Rapp, Lisa
    Ansell, Peter
    Holen, Kyle
    Reardon, David A.
    NEURO-ONCOLOGY, 2014, 16
  • [44] The Addition of Bevacizumab (BEV) to Temozolomide (TMZ) and Radiation Therapy (RT) in Newly Diagnosed Glioblastoma (GBM) Improves Progression-Free Survival (PFS) Without Adding to RT Toxicity
    Saran, F.
    Henriksson, R.
    Mason, W.
    Wick, W.
    Nishikawa, R.
    Cloughesy, T.
    Hilton, M.
    Kerloeguen, Y.
    Chinot, O. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S16 - S16
  • [45] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Saris, G
    Beroukas, K
    Karageorgis, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
  • [46] Bevacizumab in Combination With Radiotherapy and Temozolomide for PatientsWith Newly Diagnosed Glioblastoma Multiforme
    van Linde, Myra E.
    Verhoeff, Joost J. C.
    Richel, Dirk J.
    van Furth, Bwouter R.
    Reijneveld, Jaap C.
    Verheul, Henk M. W.
    Stalpers, Lukas J. A.
    ONCOLOGIST, 2015, 20 (02): : 107 - 108
  • [47] PHASE I STUDY OF VANDETANIB WITH RADIOTHERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Drappatz, Jan
    Norden, Andrew D.
    Wong, Eric T.
    Doherty, Lisa M.
    LaFrankie, Debra C.
    Ciampa, Abigail
    Kesari, Santosh
    Sceppa, Christine
    Gerard, Mary
    Phan, Phuong
    Schiff, David
    Batchelor, Tracy T.
    Ligon, Keith L.
    Young, Geoffrey
    Muzikansky, Alona
    Weiss, Stephanie E.
    Wen, Patrick Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (01): : 85 - 90
  • [48] Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
    Douglas E. Ney
    Julie A. Carlson
    Denise M. Damek
    Laurie E. Gaspar
    Brian D. Kavanagh
    B. K. Kleinschmidt-DeMasters
    Allen E. Waziri
    Kevin O. Lillehei
    Krishna Reddy
    Changhu Chen
    Journal of Neuro-Oncology, 2015, 122 : 135 - 143
  • [49] Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma
    Ney, Douglas E.
    Carlson, Julie A.
    Damek, Denise M.
    Gaspar, Laurie E.
    Kavanagh, Brian D.
    Kleinschmidt-DeMasters, B. K.
    Waziri, Allen E.
    Lillehei, Kevin O.
    Reddy, Krishna
    Chen, Changhu
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (01) : 135 - 143
  • [50] Bevacizumab, temozolomide, and radiation therapy followed by bevacizumab, temozolomide, and oral topotecan for newly-diagnosed glioblastoma multiforme (GBM).
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Coan, A. D.
    Bailey, L.
    Janney, D.
    Lu, C.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345